Allison Dorval Sells 3,350 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) Stock

Verve Therapeutics, Inc. (NASDAQ:VERV) CFO Allison Dorval sold 3,350 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $4.15, for a total transaction of $13,902.50. Following the completion of the sale, the chief financial officer now directly owns 13,280 shares of the company’s stock, valued at $55,112. The trade was a 20.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Verve Therapeutics Price Performance

Shares of NASDAQ:VERV traded down $0.06 during trading on Thursday, hitting $3.85. 2,477,105 shares of the company were exchanged, compared to its average volume of 1,431,392. Verve Therapeutics, Inc. has a 52-week low of $3.69 and a 52-week high of $9.31. The company has a market cap of $341.86 million, a PE ratio of -1.57 and a beta of 1.77. The stock has a 50 day moving average of $6.78 and a 200 day moving average of $6.05.

Verve Therapeutics (NASDAQ:VERV) last posted its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business had revenue of $13.08 million during the quarter, compared to analyst estimates of $3.94 million. Sell-side analysts forecast that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Analysts Set New Price Targets

VERV has been the subject of several recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Guggenheim reiterated a “buy” rating on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Finally, Royal Bank of Canada cut their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verve Therapeutics currently has a consensus rating of “Buy” and an average price target of $25.50.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its position in shares of Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock worth $34,000 after buying an additional 3,964 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock valued at $47,000 after acquiring an additional 8,237 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Verve Therapeutics during the 4th quarter valued at about $50,000. Erste Asset Management GmbH purchased a new position in shares of Verve Therapeutics during the third quarter worth about $56,000. Finally, Impact Partnership Wealth LLC bought a new position in shares of Verve Therapeutics in the fourth quarter worth approximately $70,000. 97.11% of the stock is owned by institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.